Abbvie (ABBV) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$64.4B

Revenue (quarter)

$17.0B

Revenue growth (year over year)

+10.16%

Gross profit (trailing twelve months)

$46.0B

Gross margin

71.48%

Net income (trailing twelve months)

$6.3B

Net income (quarter)

$3.6B

Net income growth (year over year)

+284.27%

Net margin

9.81%

Return on equity

—

EPS (trailing twelve months)

$3.54

Book value per share

−$3.36

P/E (trailing twelve months)

78.73

Price to book

—

Debt to assets

104.36%

Payout ratio

274.19%

Dividend yield

2.43%

Company profile

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

• Is Abbvie (ABBV) profitable?

  Yes. Abbvie earned $6.3B in net income over the trailing twelve months, a net margin of 9.81%.

• How much revenue does Abbvie (ABBV) make?

  Abbvie generated $64.4B in revenue over the trailing twelve months, up 10.16% year over year.

• What is ABBV's P/E ratio?

  Abbvie trades at 78.7 times trailing twelve-month earnings, on an EPS of $3.54.

• How do I buy stock in Abbvie (ABBV)?

  ABBV trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.